The development of robust clinical trial methodologies increasingly relies on advanced statistical frameworks for model selection and the characterisation of dose–response relationships. With modern ...

Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patient The unconfirmed partial response (uPR) that was observed in the first scan ...

BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma Early-phase clinical trials (EPCTs) have been ...

The Phase 2b study demonstrated a statistically significant dose-response relationship at the primary endpoint following a single administration of MM120 across four dose levels, with improvements ...

Cardiff Oncology, Inc. (NASDAQ:CRDF) announced groundbreaking Phase 1b clinical trial results for its PLK1 inhibitor onvansertib, combined with paclitaxel in metastatic triple-negative breast cancer ...

Creating a Proxy for Baseline Eastern Cooperative Oncology Group Performance Status in Electronic Health Records for Comparative Effectiveness Research in Advanced Non–Small Cell Lung Cancer ...

Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...

Phase 1b trial shows 40% response rate for onvansertib plus paclitaxel in metastatic triple-negative breast cancer, with manageable toxicity. Cardiff Oncology, Inc. announced promising results from a ...